Peptides Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
14:30
Sep 15
Ruby Justice Thelot Academic and cyber ethnographer a16z
Peptides move from gray market mainstream.
Peptides are moving from a gray-market, bodybuilding and Midwest subculture into mainstream wellness, with rising TikTok content, convergence of promotional and personal-experience content, and growing safety/skepticism discussion. The category has clear demand drivers in weight loss, muscle repair, anti-aging, and cognitive function, but also regulatory and safety risks, making it a developing theme to monitor.
Peptides
HIGH
15:08
Mar 09
Andrew Huberman Professor of Neurobiology and Ophthalmology, Stanford Unive… a16z
Peptide therapeutics going mainstream.
Non-GLP peptides like BPC-157, Pinealon, growth hormone secretagogues (tesamorelin, ipamorelin, sermorelin, MK-677), and melanotan are already widely used through compounding, gray, and black markets. The horse is out of the stable; in five years, people will take peptide cocktails for sleep, dopamine, micronutrients, and Alzheimer's protection, making peptide therapeutics mainstream.
HIGH
16:11
Feb 04
Justin Mares Founder and CEO of Truemed a16z
Peptides disruptive; pharma at risk
Peptides are a cheap, non-patentable class of compounds that appear very effective and act more like human-enhancement tools—improving energy, sex drive, inflammation, and gut health—rather than sick-care drugs. As more people experiment, peptides could produce strong positive health outcomes and be exceptionally disruptive to pharma and other healthcare players, though more research is needed and he is not fully convinced yet.
HIGH

About Peptides Investor Commentary

Across the available history and selected sources, Buzzberg tracks Peptides across 1 sources: 2 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 67% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Ruby Justice Thelot, Andrew Huberman, Justin Mares.